Anika Therapeutics
ANIK
117 hedge funds and large institutions have $115M invested in Anika Therapeutics in 2025 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 46 increasing their positions, 26 reducing their positions, and 12 closing their positions.
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
77% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 26
14% more funds holding
Funds holding: 103 → 117 (+14)
3.61% less ownership
Funds ownership: 88.45% → 84.84% (-3.6%)
14% less capital invested
Capital invested by funds: $134M → $115M (-$19.2M)
75% less call options, than puts
Call options by funds: $3K | Put options by funds: $12K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.73M |
| 2 |
BlackRock
New York
|
+$2.04M |
| 3 |
CM
Capital Management
Glen Allen,
Virginia
|
+$1.36M |
| 4 |
Two Sigma Investments
New York
|
+$763K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$546K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$6.23M |
| 2 |
AFA
Alta Fundamental Advisers
New York
|
-$4.81M |
| 3 |
TI
Trigran Investments
Northbrook,
Illinois
|
-$3.97M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.02M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$686K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Raymond James Financial
St Petersburg,
Florida
| – | -$847 | -80 | Closed |
|
|
CPG
127
Cornerstone Planning Group
Fairfield,
New Jersey
| – | -$225 | -27 | Closed |
|
|
C
128
Covestor
London,
United Kingdom
| – | +$172 | +18 | +106% |
|
129
Simplex Trading
Chicago,
Illinois
| – | +$993 | +104 | New |
|
ANIK Hedge Fund Activity: Q3 2025 in Review
117 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q3 2025, worth a combined $115M — down 14% from $134M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ANIK positions and 12 closed out — a net gain of 14 holders — while 46 added to existing stakes and 26 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $2.73M. The largest seller was Opaleye Management, exiting entirely with an estimated $6.23M sold.
- 117 institutional investors held Anika Therapeutics (ANIK) as of Q3 2025, up from 103 in Q2 2025.
- Funds reported $115M of Anika Therapeutics stock for Q3 2025, down 14% quarter-over-quarter.
- 26 funds opened new Anika Therapeutics positions in Q3 2025 and 12 closed out, a net change of +14 holders.
- The largest Anika Therapeutics buyer in Q3 2025 was Morgan Stanley, an estimated $2.73M added.
- The largest Anika Therapeutics seller in Q3 2025 was Opaleye Management, an estimated $6.23M sold.
Based on aggregated 13F filings for Q3 2025.